Table 2 Univariate and multivariate analysis of survival outcomes of hormone receptor-positive metastatic breast cancer patients.
Characteristics | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate HR (95% CI) | P | Multivariate HR (95% CI) | P | Univariate HR (95% CI) | P | Multivariatea HR (95% CI) | P | |
Initial systemic therapy | ||||||||
Initial chemotherapy | 1 | 0.0452 | 1 | 0.0472 | 1 | 0.2623 | 1 | 0.0004 |
Initial endocrine therapy | 0.84 (0.70–0.99) | 0.83 (0.69–0.99) | 0.90 (0.75–1.08) | 0.71 (0.58–0.86) | ||||
Primary metastatic disease | ||||||||
No | 1 | <0.0001 | 1 | 0.0004 | 1 | 0.0765 | — | — |
Yes | 0.69 (0.58–0.83) | 0.71 (0.59–0.86) | 0.85 (0.70–1.02) | — | ||||
Initial metastatic sites | ||||||||
Bone only | 1 | 0.0016 | 1 | 0.0158 | 1 | 0.0007 | 1 | 0.1673 |
Visceral or multiple | 1.34 (1.12–1.60) | 1.26 (1.04–1.51) | 1.40 (1.15–1.69) | 1.15 (0.94–1.41) | ||||
Hormonal status | ||||||||
Premenopausal | 1 | 0.1695 | 1 | 0.2323 | 1 | 0.0001 | 1 | 0.1434 |
Postmenopausal | 1.16 (0.94–1.43) | 1.15 (0.92–1.43) | 1.55 (1.29–1.87) | 1.23 (0.93–1.63) | ||||
Charlson Comorbidity Index (CCI) | ||||||||
CCI = 0 | 1 | 0.0368 | 1 | 0.0297 | 1 | <0.0001 | 1 | 0.0195 |
CCI > 0 | 1.20 (1.01–1.42) | 1.22 (1.02–1.47) | 1.51 (1.23–1.84) | 1.27 (1.04–1.55) | ||||
Primary endocrine resistance | ||||||||
No | 1 | 0.0215 | 1 | 0.4450 | 1 | 0.0565 | 1 | 0.2596 |
Yes | 1.32 (1.04–1.67) | 1.10 (0.86–1.42) | 1.27 (0.99–1.63) | 1.17 (0.89–1.53) | ||||
Age at MBC diagnosis | ||||||||
<65 years | 1 | 0.5689 | — | — | 1 | <0.0001 | 1 | 0.0147 |
≥65 years | 1.05 (0.89–1.25) | — | 1.64 (1.36–1.98) | 1.32 (1.06–1.65) | ||||
Primary tumour type | ||||||||
Ductal | 1 | 0.7039 | — | — | 1 | 0.8611 | — | — |
Lobular | 1.04 (0.84–1.30) | — | 1.02 (0.81-1.29) | — | ||||
Primary tumour diagnosis year | ||||||||
<2008 | 1 | 0.2060 | — | — | 1 | 0.8779 | — | — |
≥2008 | 1.12 (0.94–1.34) | — | 1.01 (0.84–1.22) | — | ||||
